

a.) Amendment to the Claims

Claims 1-15 (Cancelled)

16. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an indolocarbazole derivative, said pharmaceutically acceptable carrier and said indolocarboazole derivative being encapsulated in a liposome with an average particle size of 120 to 500 nm, said liposome consisting of lipid(s) selected from the group consisting of (i) hydrogenated soybean phosphatidylcholine and (ii) mixed lipids of hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified distearoyl phosphoethanolamine (PEG-DSPE).

Claims 17-18 (Cancelled).

19. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the lipids are mixed lipids of hydrogenated soybean phosphatidylcholine and PEG-DSPE.

20. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the lipids are hydrogenated soybean phosphatidylcholine.

Claims 21-34 (Cancelled).

35. (Previously Presented) The pharmaceutical composition according to any one of claims 16, 19, 20 or 49, wherein said liposome comprises at least two bilayers of said lipid(s).

Claims 36-41 (Cancelled)

42. (Previously Presented) A liposome preparation, comprising liposomes encapsulating an indolocarbazole derivative, said liposomes having an average particle size of 120 nm to 500 nm, wherein the liposomes consist of lipid(s) selected from the group consisting of (i) hydrogenated soybean phosphatidylcholine and (ii) mixed lipids of hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified-distearoyl phosphoethanolamine (PEG-DSPE).

43. (Previously Presented) The liposome preparation according to claim 42, wherein the lipids are mixed hydrogenated soybean phosphatidylcholine and PEG-DSPE.


44. (Previously Presented) The liposome preparation according to claim 42, wherein the lipid is hydrogenated soybean phosphatidylcholine.

Claims 45-48 (Cancelled).

49. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the average particle size of the liposomes is 130 to 186 nm.


50. (Previously Presented) The liposome preparation according to claim 42, wherein the average particle size of the liposomes is 130 to 186 nm.

51. (New) The pharmaceutical composition according to claim 16, wherein the indolocarbazole derivative is compound formula (I):



wherein R represents hydrogen or lower alkyl.

52. (New) The liposome preparation according to claim 42, wherein the indolocarbazole derivative is compound formula (I):



(I)

wherein R represents hydrogen or lower alkyl.